## 3 Results
### Advanced DPOAE Paradigms in Exposed Individuals--Frequency Sweeps  
Three frequency sweep paradigms (gross, mid-level, and high-level concentrated) were collected and a present DPOAE was defined as having a SNR of at least 6 dB and an overall DPOAE level of at least \(-\)20 dB SPL. Additionally, a significant change criterion between sessions was defined as a change of \(\pm\)6 dB at two or more consecutive frequencies. As some patients had more sessions than others, it should be noted that if significant changes were found between baseline testing and a subsequent test, but the DPOAE level was \(<\)\(\pm\)6 dB of baseline values at the final testing session, that patient's measurements will still be qualified as a clinically significant change. Eight out of the 12 (66%) patients had significant changes in their measured DPOAEs for gross discrete frequency sweeps (patients 1, 4, 6, 8, 9, 10, 16 and 18). Patient 4 completed five testing sessions for this paradigm and significant changes between baseline testing and sessions were observed in session three and four, but session five reflected DPOAE levels returning to the baseline level. Defined significant changes between baseline and final test sessions were observed for patients 6, 8, and 10 (session 4 for patients 6 and 8 and session 3 for patient 10, despite showing changes in the second testing session). Interestingly, these three patients also demonstrated significant changes in lower frequency DPOAEs. Patient 9 demonstrated significant changes between baseline and both subsequent sessions, shown in the top panel of Figure 1. Patients 1, 16 and 18 had a significant change from baseline to their second (and final) testing session. Half of the patients showing significant changes received oxaliplatin and the other half received carboplatin. Eight of the 10 patients (80%) demonstrated significant changes in their mid-level (62/52 dB FPL) concentrated frequency sweep DPOAE levels (patients 1, 4, 6, 8, 9, 10, 16, and 18). Changes in this paradigm for patient 9 are shown in bottom left panel of Figure 1. Where multiple sessions were performed, the frequency ranges showing significant changes were consistent across subsequent sessions for all patients, see Table 2 for details. All of the patients with changes in this paradigm also had changes in the high-level concentrated frequency sweep paradigm, except for patient 6. All seven patients demonstrated changes for both paradigms in the same general frequency regions; however, the mid-level paradigm had larger ranges of consecutive frequencies with changes. As with the gross frequency sweep results, half of the patients with defined significant changes received oxaliplatin and the other half received carboplatin. Figure 1: Gross and concentrated frequency sweep results for patient 9. The **top panel** represents the results from the gross discrete frequency sweep (L\({}_{1}\)/L\({}_{2}\) = 62/52 dB forward pressure level (FPL)), while the **bottom left panel** illustrates the results from the high-level concentrated frequency sweep (L\({}_{1}\) = L\({}_{2}\) = 72 dB FPL), and the **bottom right panel** depicts the data collected for the mid-level concentrated frequency sweeps (L\({}_{1}\)/L\({}_{2}\) = 62/52 dB FPL). Black triangles, red squares, and grey diamonds indicate sessions 1, 2, and 3, respectively. The thin dashed black line indicates the average noise floor for all three sessions. Note, sessions and trials are synonymous. Seventy-five percent (9/12 patients) had significant changes in their DPOAE concentrated frequency sweep with high-level stimuli (72/72 dB FPL). Patients 1, 2 and 16 had changes from baseline measures to their second (and final) session. Patients 4, 7, 8, 9, 10 and 18 had defined significant changes from baseline to at least one subsequent session and the final session.